Evidence map›Paper›PMID 34120487›Full record

ReviewJournal of diabetes science and technology2022

Products for Monitoring Glucose Levels in the Human Body With Noninvasive Optical, Noninvasive Fluid Sampling, or Minimally Invasive Technologies.

Trisha Shang, Jennifer Y Zhang, Andreas Thomas, Mark A Arnold, Beatrice N Vetter, Lutz Heinemann, David C Klonoff

Open access · bronzeAbstract readReview
In one paragraph

Review in Journal of diabetes science and technology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Trisha ShangDiabetes Technology Society, Burlingame, California, USA.ORCID 0000-0001-9687-9336
Jennifer Y ZhangDiabetes Technology Society, Burlingame, California, USA.ORCID 0000-0002-3374-9777
Andreas ThomasAGDT (Working group of Diabetes Technology), Germany, Ulm, Germany.ORCID 0000-0002-6549-2793
Mark A ArnoldUniversity of Iowa, Department of Chemistry, Iowa City, Iowa, USA.ORCID 0000-0001-9375-1863
Beatrice N VetterFoundation for Innovative New Diagnostics, Geneva, Switzerland.ORCID 0000-0002-7898-472X
Lutz HeinemannScience Consulting in Diabetes GmbH, Neuss, Germany.ORCID 0000-0003-2493-1304
David C KlonoffMills-Peninsula Medical Center, San Mateo, California, USA.ORCID 0000-0001-6394-6862
Diabetes Technology Society · USFIND · CHMills Peninsula Health Services · USUniversity of Iowa · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundConventional home blood glucose measurements require a sample of blood that is obtained by puncturing the skin at the fingertip. To avoid the pain associated with this procedure, there is high demand for medical products that allow glucose monitoring without blood sampling. In this review article, all such products are presented.

methodsIn order to identify such products, four different sources were used: (1) PubMed, (2) Google Patents, (3) Diabetes Technology Meeting Startup Showcase participants, and (4) experts in the field of glucose monitoring. The information obtained were filtered by using two inclusion criteria: (1) regulatory clearance, and/or (2) significant coverage in Google News starting in the year 2016, unless the article indicated that the product had been discontinued. The identified bloodless monitoring products were classified into three categories: (1) noninvasive optical, (2) noninvasive fluid sampling, and (3) minimally invasive devices.

resultsIn total, 28 noninvasive optical, 6 noninvasive fluid sampling, and 31 minimally invasive glucose monitoring products were identified. Subsequently, these products were characterized according to their regulatory, technological, and consumer features. Products with regulatory clearance are described in greater detail according to their advantages and disadvantages, and with design images.

conclusionsBased on favorable technological features, consumer features, and other advantages, several bloodless products are commercially available and promise to enhance diabetes management. Paths for future products are discussed with an emphasis on understanding existing barriers related to both technical and non-technical issues.

Indexed as

Blood Glucose Self-MonitoringDiabetes MellitusBlood GlucoseHuman BodyHumansTechnologyBlood Glucosefluid samplingglucoseinvasiveminimally invasivenoninvasiveoptical

Identifiers

PMID34120487
PMCPMC8721558
OpenAlexW3168692744

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.